Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. is Guideline
should not be considered exclusive of other methods of care reasonably directed at obtaining the
same results. e ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician aer consideration of each individual patient situation. Neither IGC,
the medical associations, nor the authors endorse any product or service associated with the
distributor of this clinical reference tool.
Source
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism:
prepared by the American yroid Association task force on thyroid hormone
replacement. yroid, a Mary Ann Liebert, Inc. publication. 2014;24(12):1670-751.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2015 All rights reserved
ATAHYPO15043a
Abbreviations
ATA, American yroid Association; LT4, levothyroxine; T3, triiodothyronine; T4,
thyroxine; TRIAC, 3,5,3′-triiodothyroacetic acid; TRα, thyroid hormone receptor-α;
TRβ, thyroid hormone receptor-β; TSH, thyrotropin
The American College of Physicians' Guideline
Grading System
Quality of Evidence
Strength of Recommendation
Benefits clearly outweigh
risks and burden or
risks and burden clearly
outweigh benefits
Benefits finely balanced
with risks and burden
H = High
S = Strong W = Weak M = Moderate
L = Low
I = Insufficient evidence to determine net benefits or risks
Reprinted, with permission, from e Development of Clinical Practice Guidelines and Guidance
Statements of the American College of Physicians. Ann Intern Med 2010;153:194–199.
